ZANDER THERAPEUTICS, INC
ZANDER THERAPEUTICS, INC (ZANDER): 2 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.8 months
D/E -1.58 · 0% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for ZANDER THERAPEUTICS, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$5K
Quarterly Burn
$42K
Runway
3.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in ZANDER THERAPEUTICS, INC's pipeline?
ZANDER THERAPEUTICS, INC (ZANDER) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ZANDER THERAPEUTICS, INC's lead drug candidate?
ZANDER THERAPEUTICS, INC's most advanced tracked candidate is zan-100 (Preclinical) for veterinary cancer therapy.
What is ZANDER THERAPEUTICS, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ZANDER THERAPEUTICS, INC has approximately 3.8 months of cash runway.
Get the full picture on ZANDER THERAPEUTICS, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.